"It has been a privilege to be a part of the team that developed this technology at its conception through its clinical translation. The emerging BIND-014 clinical data showing signals of efficacy even at relatively low doses validates the potential for the revolutionary impact of nanomedicines and is a paradigm shift for the treatment of cancer." said Philip W. Kantoff, MD, Chief Clinical Research Officer at DFCI, Professor of Medicine at Harvard Medical School, and study co-author.
"It is wonderful to witness a world-class team of scientists, engineers, physicians, for-profit and non-project organizations converge to develop this potentially revolutionary technology for treatment of cancers. The effectiveness of this team has been remarkable and serves as model for translational research" said Edward J. Benz, Jr. MD, President of DFCI, Richard and Susan Smith Professor of Medicine at Harvard Medical School.
The research and development of the first targeted programmable nanomedicine to show anti-tumor effects in humans represents the culmination of more than a decade of investigation initially carried out in academic labs at BWH and MIT, and supported by funding from the National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, The David H. Koch Institute for Integrative Cancer Research at MIT, the Prostate Cancer Foundation, philanthropic gift from David H. Koch, and the Dana-Farber Harvard Cancer Center Prostate Cancer SPORE; and subsequently carried out in the laboratories of BIND Biosciences leading to the development of BIND-014, and supported by funding from the National Cancer Institute, National Institute of Standards and Technology and BIND Biosciences.
BIND Biosciences was launched in 2007 based on technologies that were licensed from BWH and MIT and developed, respectively, in the laborator
|Contact: Marjorie Montemayor-Quellenberg|
Brigham and Women's Hospital